CA2422275A1 - Compositions and methods for inhibition of hiv-1 infection - Google Patents

Compositions and methods for inhibition of hiv-1 infection Download PDF

Info

Publication number
CA2422275A1
CA2422275A1 CA002422275A CA2422275A CA2422275A1 CA 2422275 A1 CA2422275 A1 CA 2422275A1 CA 002422275 A CA002422275 A CA 002422275A CA 2422275 A CA2422275 A CA 2422275A CA 2422275 A1 CA2422275 A1 CA 2422275A1
Authority
CA
Canada
Prior art keywords
hiv
cell
composition
antibody
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002422275A
Other languages
English (en)
French (fr)
Inventor
William C. Olson
Paul J. Maddon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progenics Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/002633 external-priority patent/WO2001055439A1/en
Application filed by Individual filed Critical Individual
Publication of CA2422275A1 publication Critical patent/CA2422275A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002422275A 2000-09-15 2001-09-14 Compositions and methods for inhibition of hiv-1 infection Abandoned CA2422275A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US66321900A 2000-09-15 2000-09-15
US09/663,219 2000-09-15
USPCT/US01/02633 2001-01-26
PCT/US2001/002633 WO2001055439A1 (en) 2000-01-28 2001-01-26 Compositions and methods for inhibition of hiv-1 infection
US26673801P 2001-02-06 2001-02-06
US60/266,738 2001-02-06
US09/912,824 US7138119B2 (en) 2000-09-15 2001-07-25 Compositions and methods for inhibition of HIV-1 infection
US09/912,824 2001-07-25
PCT/US2001/028756 WO2002022077A2 (en) 2000-09-15 2001-09-14 Compositions and methods for inhibition of hiv-1 infection

Publications (1)

Publication Number Publication Date
CA2422275A1 true CA2422275A1 (en) 2002-03-21

Family

ID=27485936

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002422275A Abandoned CA2422275A1 (en) 2000-09-15 2001-09-14 Compositions and methods for inhibition of hiv-1 infection

Country Status (6)

Country Link
US (2) US7138119B2 (https=)
EP (1) EP1322332A4 (https=)
JP (1) JP2004518624A (https=)
AU (2) AU2001290925C1 (https=)
CA (1) CA2422275A1 (https=)
WO (1) WO2002022077A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0847452B1 (en) * 1995-06-07 2009-04-01 Progenics Pharmaceuticals, Inc. Monoclonal antibody for inhibiting hiv-1 envelope glycoprotein mediated membrane fusion
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US20040086528A1 (en) * 1996-06-14 2004-05-06 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting HIV-1 infection
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6548636B2 (en) * 2000-02-29 2003-04-15 Progenics Pharmaceuticals, Inc. Sulfated CCR5 peptides for HIV-1 infection
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US20020146415A1 (en) * 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
CA2522690A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
FI20040704A0 (fi) * 2004-05-21 2004-05-21 Ari Hinkkanen Replikatiivisen viruksen tai sen rekombinantin käyttö terapiassa
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
CA2616189C (en) * 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
AU2007286451A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against CCR5 and an antifusogenic peptide
KR20090052358A (ko) 2006-09-29 2009-05-25 에프. 호프만-라 로슈 아게 Ｃｃｒ5 에 대한 항체 및 이의 용도
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
WO2009014638A2 (en) * 2007-07-19 2009-01-29 Progenics Pharmaceuticals, Inc. Methods of inhibiting infection by diverse subtypes of drug-resistant hiv-1
US20100186234A1 (en) * 2009-01-28 2010-07-29 Yehuda Binder Electric shaver with imaging capability
EP2638072A4 (en) 2010-11-12 2014-05-07 Univ Rockefeller FUSION PROTEINS FOR HIV THERAPY
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
ES2949060T3 (es) * 2013-12-02 2023-09-25 Univ Columbia Mejora de la potencia y amplitud de anticuerpos neutralizantes del VIH-1 mediante el anclaje de receptores celulares utilizando anticuerpos biespecíficos con arquitectura nativa
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
UY36990A (es) * 2015-11-21 2017-11-30 Fundació Privada Inst De Recerca De La Sida-Caixa (Irsicaixa) Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria
KR20200003915A (ko) * 2017-05-10 2020-01-10 알바후나 테라퓨틱스, 에스.엘. 높은 이중 ＨＩＶ 항바이러스 활성과 면역조절 활성을 갖는 Ｆｃ-융합 단백질 유도체
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886743A (en) 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5126433A (en) 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5854400A (en) 1987-05-29 1998-12-29 Tanox, Inc. Monoclonal antibodies which neutralize HIV-1 infection
US5215913A (en) 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
US5071964A (en) 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US5668149A (en) * 1990-01-26 1997-09-16 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of human immunodeficiency virus-1 infectivity in human cells
WO1992001451A1 (en) 1990-06-12 1992-02-06 Board Of Regents, The University Of Texas System Method for killing hiv-infected cells
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
US5449608A (en) 1993-03-22 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Parvovirus B19 receptor and parvovirus B19 detection
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5464963A (en) * 1993-08-27 1995-11-07 Motoman Inc. Sealing arrangement for a laser enclosure
US5603933A (en) * 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins
US5504003A (en) 1994-03-08 1996-04-02 Human Genome Sciences, Inc. Macrophage inflammatory protein-3 and -4
FR2727221B1 (fr) 1994-11-23 1996-12-27 Kodak Pathe Procede de communication d'informations numeriques et systeme pour la mise en oeuvre du procede
MX9709849A (es) 1995-06-06 1998-03-29 Human Genome Sciences Inc Receptor de quimiocina de la proteina g humana o hdgnr10.
JPH10510719A (ja) 1995-06-06 1998-10-20 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒトｇタンパク質ケモカインレセプターｈｄｇｎｒ１０
US20040151719A1 (en) 1995-06-06 2004-08-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
EP1146122A3 (en) 1995-06-06 2003-12-03 Human Genome Sciences, Inc. Human G-protein chemokine receptor HDGNR10 (CCR5 receptor)
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) * 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
EP0847452B1 (en) 1995-06-07 2009-04-01 Progenics Pharmaceuticals, Inc. Monoclonal antibody for inhibiting hiv-1 envelope glycoprotein mediated membrane fusion
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
WO1997026009A1 (en) 1996-01-17 1997-07-24 Progenics Pharmaceuticals, Inc. Compounds capable of inhibiting hiv-1 infection
EP1199360A3 (en) * 1996-03-01 2002-05-02 Euroscreen S.A. Active and inactive CC-chemokine receptors and nucleic acid molecules encoding said receptor
US6344545B1 (en) 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US6107019A (en) 1996-06-14 2000-08-22 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
WO1997037005A1 (en) 1996-04-02 1997-10-09 Progenics Pharmaceuticals, Inc. Method for preventing hiv-1 infection of cd4+ cells
US5939320A (en) 1996-05-20 1999-08-17 New York University G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
US6258527B1 (en) 1996-05-20 2001-07-10 The Aaron Diamond Aids Research Center Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
AU3375697A (en) 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
AU735460B2 (en) 1996-06-14 2001-07-12 Aaron Diamond Aids Research Center, The Uses of a chemokine receptor for inhibiting HIV-1 infection
US20040086528A1 (en) 1996-06-14 2004-05-06 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting HIV-1 infection
AU3505397A (en) 1996-06-25 1998-01-14 Trustees Of The University Of Pennsylvania, The Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
US5994515A (en) * 1996-06-25 1999-11-30 Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US6100087A (en) 1998-03-11 2000-08-08 City Of Hope Ribozymes targeted to human CCR5 mRNA
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
ES2296416T3 (es) 1998-12-16 2008-04-16 Progenics Pharmaceuticals, Inc. Anticuerpo pa14 frente a ccr5.
US20040228869A1 (en) 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US6692745B2 (en) 2000-01-28 2004-02-17 Arogenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US20020048786A1 (en) * 2000-02-09 2002-04-25 Rosen Craig A. Human G-protein Chemokine Receptor HDGNR10
US6548636B2 (en) * 2000-02-29 2003-04-15 Progenics Pharmaceuticals, Inc. Sulfated CCR5 peptides for HIV-1 infection
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20030092632A1 (en) * 2001-02-28 2003-05-15 Tatjana Dragic Sulfated CCR5 peptides for HIV-1 infection
US20030003440A1 (en) 2001-03-14 2003-01-02 Lucia Lopalco Novel CCR5 epitope and antibodies against it
US20020146415A1 (en) 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
CN1649591A (zh) 2001-04-19 2005-08-03 布里斯托尔-迈尔斯斯奎布公司 可用作hiv逆转录酶抑制剂的三环化合物
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
DE60324664D1 (de) 2002-02-22 2008-12-24 Pdl Biopharma Inc Anti-ccr5 antikörper
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
AU2004251228B2 (en) 2003-05-16 2008-04-24 University Of Maryland Biotechnology Institute Compositions for down-regulation of CCR5 expression and methods of use therefor
US20050131042A1 (en) 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
CA2616189C (en) 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients

Also Published As

Publication number Publication date
WO2002022077A2 (en) 2002-03-21
AU2001290925C1 (en) 2009-01-22
US20020106374A1 (en) 2002-08-08
US7736649B2 (en) 2010-06-15
JP2004518624A (ja) 2004-06-24
EP1322332A4 (en) 2006-06-21
WO2002022077A3 (en) 2002-06-20
US7138119B2 (en) 2006-11-21
US20070020280A1 (en) 2007-01-25
AU9092501A (en) 2002-03-26
AU2001290925B2 (en) 2006-07-13
EP1322332A2 (en) 2003-07-02

Similar Documents

Publication Publication Date Title
AU2001290925B2 (en) Compositions and methods for inhibition of HIV-1 infection
US6692745B2 (en) Compositions and methods for inhibition of HIV-1 infection
AU2001290925A1 (en) Compositions and methods for inhibition of HIV-1 infection
US7060273B2 (en) Methods for inhibiting HIV-1 infection
US20020146415A1 (en) Methods for inhibiting HIV-1 infection
US7851600B2 (en) Anti-CCR5 antibody
US20070274986A1 (en) Compositions comprising anti-CCR5 antibody
CA2476901C (en) Anti-ccr5 antibody
US20240285790A1 (en) Antibody-cd4 conjugates and methods of using the same
CA2355607A1 (en) Anti-ccr5 antibody
WO1997046697A2 (en) Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections
Vermeire et al. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor
Vermeire et al. CD4 down-modulating compounds with potent anti-HIV activity
US20030211470A1 (en) CD4-IgG2-based salvage therapy of HIV-1 infection
AU2007254697B2 (en) Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto-I
HK1072272B (en) Anti-ccr5 antibody

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued